FDA Approves Dual-Energy Catheter Ablation Platform - Report - MDSpire
Advertisement
FDA Approves Dual-Energy Catheter Ablation Platform
The platform integrates with the CARTO ecosystem and enables physicians to use either pulsed field or radiofrequency energy based on patient anatomy and case complexity.
Clinical Report: FDA Approves Dual-Energy Catheter Ablation Platform
Overview
The FDA has approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, enabling electrophysiologists to utilize both pulsed field and radiofrequency energy through a single catheter.
Background
The approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform represents a significant advancement in catheter ablation technology, which is crucial for treating arrhythmias. The ability to deliver both pulsed field and radiofrequency energy allows for tailored approaches based on individual patient anatomy and procedural complexity.
Data Highlights
No numerical data available in the source material.
Key Findings
The platform integrates pulsed field and radiofrequency energy delivery into a single catheter.
It is compatible with the CARTO ecosystem, enhancing mapping and imaging capabilities.
More than one million patients have been treated with the THERMOCOOL SMARTTOUCH SF catheter platform in the US.
The first US procedures using the platform are expected to begin in summer 2023.
Electrophysiologists can choose the energy type based on the needs of each procedure.
Clinical Implications
The Dual Energy THERMOCOOL SMARTTOUCH SF Platform allows electrophysiologists to choose the energy type based on the needs of each procedure.
Conclusion
The FDA's approval of this dual-energy platform marks a development in catheter ablation technology.
